Avoralstat (BCX4161)
98%
- Product Code: 110364
CAS:
918407-35-9
| Molecular Weight: | 513.54 g./mol | Molecular Formula: | C₂₈H₂₇N₅O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Avoralstat (BCX4161) is primarily investigated for its potential in treating hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. It functions as a plasma kallikrein inhibitor, targeting the underlying mechanism of HAE by preventing the overproduction of bradykinin, a peptide responsible for swelling and pain. By inhibiting kallikrein, it helps reduce the frequency and severity of HAE attacks, improving patients' quality of life. Clinical studies have explored its efficacy and safety as an oral therapy, offering a convenient alternative to injectable treatments. Its development represents a significant step forward in managing HAE, particularly for patients seeking non-invasive treatment options.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿26,880.00 |
+
-
|
Avoralstat (BCX4161)
Avoralstat (BCX4161) is primarily investigated for its potential in treating hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. It functions as a plasma kallikrein inhibitor, targeting the underlying mechanism of HAE by preventing the overproduction of bradykinin, a peptide responsible for swelling and pain. By inhibiting kallikrein, it helps reduce the frequency and severity of HAE attacks, improving patients' quality of life. Clinical studies have explored its efficacy and safety as an oral therapy, offering a convenient alternative to injectable treatments. Its development represents a significant step forward in managing HAE, particularly for patients seeking non-invasive treatment options.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :